Advancing Microbiome Frontiers: Specialized Research Service for Adlercreutzia equolifaciens
The human microbiome is no longer viewed merely as a passenger of our digestive system; it is a complex metabolic organ capable of transforming dietary compounds into potent bioactive molecules. Among these, equol stands out as a metabolite of immense therapeutic potential, and Adlercreutzia equolifaciens serves as its primary microbial architect.
As a leading Contract Research Organization (CRO) specializing in Live Biotherapeutic Products (LBPs), Creative Biolabs bridges the gap between discovery and the clinic. Our mission is to provide global pharmaceutical and biotech innovators with the high-resolution data and specialized preclinical models necessary to harness A. equolifaciens for the next generation of microbiome-based medicine.
Overview: The Biology and Significance of Adlercreutzia equolifaciens
Adlercreutzia equolifaciens is a gram-positive, non-spore-forming, anaerobic bacterium belonging to the family Eggerthellaceae. While it represents a relatively small fraction of the human gut microbiota, its functional impact is disproportionately large due to its unique metabolic capability: the conversion of daidzein (a soy isoflavone) into S-equol.
The Equol Production Pathway
Unlike many other gut bacteria that may only partially metabolize polyphenols, A. equolifaciens possesses a specific suite of enzymes—including daidzein reductase (DZNR), dihydrodaidzein reductase (DHDR), and tetrahydrodaidzein reductase (THDR)—that facilitate the complete reduction of daidzein.
Why Equol Matters:
Estrogenic Modulation: S-equol has a high affinity for estrogen receptor β (ERβ), allowing it to modulate hormonal signaling without the proliferative risks associated with ERα activation.
Antioxidant Properties: It exhibits potent radical-scavenging capabilities.
Bioavailability: Unlike its precursor daidzein, equol is highly bioavailable and stays in the systemic circulation longer, making it a "postbiotic" of significant interest.
By targeting this strain as a Live Biotherapeutic, researchers aim to overcome the "non-producer" phenotype found in approximately 50-70% of the Western population who lack the native bacteria to produce equol.
Our Services: Specialized Preclinical Solutions
Navigating the complexities of anaerobic microbiology and isoflavone metabolism requires specialized infrastructure. We offer a comprehensive suite of services tailored specifically for Adlercreutzia equolifaciens research.
Anaerobic Isolation: Custom isolation from human or environmental samples using specialized selective media.
Genomic Profiling: Full-genome sequencing (WGS) to identify the equol-producing operon and ensure the absence of virulence factors or antibiotic resistance genes (AMR).
Phenotypic Assays: Quantitative measurement of equol production via LC-MS/MS in various growth conditions.
Metabolic Flux Analysis: Tracing the conversion rates of daidzein to dihydrodaidzein and finally to equol.
Cell Culture Models: Assessing the anti-inflammatory effects of A. equolifaciens supernatants on intestinal epithelial cells (Caco-2) or immune cells (RAW 264.7).
Co-culture Systems: Studying the interaction of A. equolifaciens with other commensal bacteria to understand ecological fitness.
The decline in estrogen during menopause leads to hot flashes and bone density loss. Since equol acts as a selective estrogen receptor modulator (SERM), A. equolifaciens is being researched as a "natural hormone replacement therapy" to alleviate vasomotor symptoms without the side effects associated with synthetic estrogens.
There is significant interest in the role of equol-producing bacteria in reducing the risk of breast and prostate cancers. The anti-androgenic effects of equol make A. equolifaciens a candidate for adjunctive therapy in prostate health.
Emerging evidence links equol to reduced neuroinflammation. Research is ongoing into whether A. equolifaciens can mitigate the progression of neurodegenerative diseases, such as Alzheimer's, by crossing the blood-brain barrier via its metabolites.
Why Choose Us?
Anaerobic Expertise
State-of-the-art anaerobic chambers and specialized handling for highly oxygen-sensitive strains.
Integrated Platform
From "Gene to Lead"—we handle genomics, metabolomics, and animal modeling under one roof.
Precision Analytical Chemistry
High-sensitivity LC-MS/MS platforms specifically calibrated for isoflavone metabolite quantification.
Regulatory Insight
Deep understanding of FDA/EMA guidelines for Live Biotherapeutic Products (LBPs).
Customization
Flexible study designs tailored to the specific metabolic nuances of Adlercreutzia.
Partner With Us Today
The exploration of Adlercreutzia equolifaciens represents a shift toward precision micro-metabolism. We are no longer just looking at "good" or "bad" bacteria; we are looking at specific enzymatic catalysts that can convert dietary components into potent pharmacological agents within the host. As the scientific community continues to unravel the link between equol and systemic health, the demand for rigorous, high-fidelity preclinical data has never been higher.
Our company is dedicated to bridging the gap between benchtop discovery and clinical application. By providing the tools, the expertise, and the specialized environment required to study this unique anaerobe, we empower your team to focus on the science while we handle the technical complexities of microbiome research. The path to a breakthrough Live Biotherapeutic begins with a single, well-characterized strain. Whether you are investigating Adlercreutzia equolifaciens for metabolic health, women's wellness, or oncology, our team is ready to provide the preclinical support you need to succeed.
Is Adlercreutzia equolifaciens considered a probiotic?
While it is a natural inhabitant of the gut, it is currently classified primarily as a candidate for a Live Biotherapeutic Product (LBP) in clinical contexts, or a "Next-Generation Probiotic" (NGP).
Can this strain grow in standard aerobic conditions?
No, A. equolifaciens is an obligate anaerobe. It requires strictly oxygen-free environments for growth and metabolic activity, which is why our specialized anaerobic facility is crucial for research.
How do you verify if a strain is a "producer"?
We use a combination of genomic screening (looking for the thd operon) and functional assays using HPLC or LC-MS/MS to detect the conversion of daidzein to equol in vitro.
What animal models are best for this research?
We recommend germ-free mice or antibiotic-treated mice "humanized" with equol-producing or non-producing microbiotas to isolate the effects of the Adlercreutzia strain.
Online Inquiry
For Research Use Only. Not intended for use in
food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
